Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sristi Suman Jayaswal

Why Citi Is Sounding the Alarm on Moderna Stock

Moderna (MRNA) skyrocketed to fame during the pandemic. Its Covid-19 vaccine put the biotech on the map, sent sales soaring, and made the company one of Wall Street’s hottest names. Then the pandemic boom ran out of steam. Vaccine demand cooled, revenues took a hit, and the stock spent years trying to find its footing.

Fast-forward to 2026; the shares have soared roughly sixfold in 2026 alone, fueled by excitement around its personalized cancer vaccine developed with Merck (MRK). The rally accelerated after positive Phase 3 melanoma results, sending MRNA stock sharply higher as investors began pricing in a much bigger oncology opportunity.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.